Blog of Signaling Pathways

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

35 views | Jan 11 2024

The identification of ELAVL3 as a pivotal regulator in neuroendocrine prostate cancer, its interplay with MYCN, RICTOR mRNA, and extracellular vesicles, coupled with the efficacy of pyrvinium pamoate in suppressing tumor growth and improving survival, presents a promising avenue for targeted therapies and drug repurposing strategies in this aggressive cancer. [Read the Full Post]

Validation of a highly sensitive HaloTag-based assay to evaluate the potency of a novel class of allosteric β-Galactosidase correctors

13 views | Jan 11 2024

SEE-Tx® technology identified STAR compounds that effectively enhanced the transport and activity of β-galactosidase enzymes, showcasing promise for treating lysosomal storage disorders associated with GLB1 mutations. [Read the Full Post]

Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy

32 views | Jan 11 2024

The repurposing of veterinary polyether ionophores, supported by in vitro and in vivo studies, demonstrates promising potential in inhibiting SARS-CoV-2 through multi-target interactions, synergized by Zn2+ supplementation, highlighting a compelling avenue for novel therapeutic strategies against COVID-19. [Read the Full Post]

Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis

52 views | Jan 11 2024

This comprehensive review highlights the evolving landscape of JAK inhibitors in myelofibrosis treatment, emphasizing their varying efficacy in addressing symptoms and the need for further studies to ascertain their precise impact and facilitate more personalized therapeutic approaches. [Read the Full Post]

Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype

52 views | Jan 11 2024

This study's establishment of a physiologically relevant in vitro system for TAM polarization unveils BMS-794833 as a potent inhibitor, independent of primary targets but reliant on multiple signaling pathways, offering a promising strategy to reprogram TAMs and suppress cancer growth. [Read the Full Post]

MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer

52 views | Jan 10 2024

MTX-211 demonstrates promising potential as a therapeutic agent for bladder cancer by inhibiting cell proliferation through the Keap1/NRF2/GCLM signaling pathway and depleting intracellular GSH levels. [Read the Full Post]

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status

29 views | Jan 10 2024

This study presents compelling evidence that epigenetic reactivation of Tumor Suppressor Candidate 3 (TUSC3) can significantly enhance Temozolomide (TMZ) sensitivity in both MGMT-promoter-hypermethylated (MGMT-M) and MGMT-promoter-hypomethylated (MGMT-UM) glioblastoma stem cells, offering a potential breakthrough in addressing TMZ resistance and improving outcomes in glioblastoma patients. [Read the Full Post]

Outcomes and Safety of Suprapubic vs Urethral Catheterization Following Pelvic Fascia Sparing Robotic Prostatectomy

26 views | Jan 10 2024

Suprapubic catheters post Pelvic Fascia Sparing Robotic-Assisted Radical Prostatectomy (PFS-RARP) exhibit a notable advantage over urethral catheters by enabling earlier continence recovery and higher continence rates at catheter removal, potentially enhancing overall patient satisfaction without compromising quality of life. [Read the Full Post]

In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent

29 views | Jan 10 2024

The study successfully identified thirteen metabolites of IOX2 in human hepatocytes, with hydroxyquinolinyl-IOX2 emerging as a major biomarker, emphasizing the critical role of glucuronide hydrolysis for enhanced detectability in urine, offering valuable insights for anti-doping testing. [Read the Full Post]

Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 and Other DNA and RNA Viruses with Diverse Genomes and Life Cycles

0 views | Jan 10 2024

The discovery of aurora kinase inhibitors significantly impairing HSV-1 gene expression and replication, while also impacting other viral families, illuminates a promising avenue for broad-spectrum antiviral therapies targeting these pivotal cellular kinases. [Read the Full Post]

Targeting the survival kinase DYRK1B: A novel approach to overcome radiotherapy-related treatment resistance

27 views | Jan 09 2024

Targeting the stress-enhanced survival kinase DYRK1B alongside irradiation demonstrates a synergistic effect in eliminating colorectal tumor cells under harsh environmental stressors, offering a promising strategy to overcome treatment resistance. [Read the Full Post]

HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation

33 views | Jan 09 2024

The study unveils a novel relationship where HMGA1 upregulates FGF19, driving pancreatic cancer progression and stroma formation, establishing FGF19 as a potential therapeutic target for a distinct, highly aggressive subset of PDAC. [Read the Full Post]

Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice

25 views | Jan 09 2024

The study's findings on 5-HT1A receptor expression and responsiveness to agonists in juvenile Fmr1 knockout mice suggest a promising therapeutic potential of 5-HT1AR agonists for managing auditory hypersensitivity and seizures in young individuals with Fragile X syndrome. [Read the Full Post]

Target-based virtual screening, computational multiscoring docking and molecular dynamics simulation of small molecules as promising drug candidate affecting kinesin-like protein KIFC1

37 views | Jan 09 2024

The computational analysis identified mcule-4895338547 as a promising small-molecule inhibitor targeting KIFC1, showing strong binding affinity and favorable properties, holding potential for further exploration in cancer treatment. [Read the Full Post]

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses

21 views | Jan 09 2024

"Our study reveals that the AURKA inhibitor MLN8237 enhances the effectiveness of immunotherapy in tumor cells by upregulating PD-L1 expression, presenting a promising approach to augmenting anti-tumor responses and potentially overcoming drug resistance in targeted therapy." [Read the Full Post]

Vaccarin alleviates cisplatin-induced acute kidney injury via decreasing NOX4-derived ROS

24 views | Jan 08 2024

The study reveals that vaccarin exhibits a protective effect against cisplatin-induced acute kidney injury by mitigating oxidative stress, inhibiting cell death pathways, specifically necroptosis and apoptosis, and reducing inflammation, potentially mediated through the inhibition of NOX4. [Read the Full Post]

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

26 views | Jan 08 2024

The evolving understanding of PD123319's effects challenges its traditional classification as an AT2 receptor antagonist, suggesting potential agonist-like actions at lower doses and highlighting the intricate balance between AT1 and AT2 receptor stimulation within the renin-angiotensin system. [Read the Full Post]

The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment

29 views | Jan 08 2024

Research examining metabolic pathways in Group 3 medulloblastoma cells has unveiled promising therapeutic strategies, showcasing inhibitors that target NADH shuttles and mitochondrial function, offering hope for more effective treatments in this aggressive tumor subtype. [Read the Full Post]

Percutaneous coronary intervention with ridaforolimus-eluting stents in long lesions: the BIONICS 38 mm prospective trial

59 views | Jan 08 2024

The study evaluating the 38 mm ridaforolimus-eluting stent in percutaneous coronary intervention for long lesions demonstrated high efficacy, low rates of major adverse cardiovascular events, and successful treatment outcomes, supporting its safety and effectiveness in this patient group. [Read the Full Post]

Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma

32 views | Jan 08 2024

The comprehensive analysis of hepatocellular carcinoma mutations, particularly highlighting TP53 and LRP1B, suggests a tailored prognostic risk model for TP53 wild-type patients and identifies potential therapeutic implications, such as AM580, opening avenues for personalized treatment approaches. [Read the Full Post]